---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-018626"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:19:30.729494+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex provides clinical updates: Acclaim-1 Phase 2 expansion approved, patient dosing delayed to Q3 2023

## Summary
- Acclaim-1 Phase 1 completed; SRC approved Phase 2 expansion at 0.12 mg/kg; first patient expected Q3 2023.
- Acclaim-2 enrollment slower than anticipated; Phase 1 dose escalation completion expected Q1 2024.
- Acclaim-3 protocol filed Nov 2022; first patient expected Q3 2023; delays due to LNP CDMO transition.
- Company has enough REQORSA supply through Sep 2023; plans to produce more but trials would be delayed if not.

## SEC filing metadata
- accession: 0001437749-23-018626
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774923018626/0001437749-23-018626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774923018626/gnpx20230615_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-018626
- JSON: https://secwatch.observer/filing/0001437749-23-018626.json
- Plain text: https://secwatch.observer/filing/0001437749-23-018626.txt

## Key facts
- Shareholder Votes
  Genprex, Inc. shareholders approved Election of Class III Directors at the 2023-06-27 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-27
  source text: The Class III director nominees, Jose Antonio Moreno Toscano and J. Rodney Varner, were elected to serve until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the Class III directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Jose Antonio Moreno Toscano 4,856,975 3,471,721 18,051,580 J. Rodney Varner 6,899,410 1,429,286 18,051,580
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923018626/0001437749-23-018626-index.htm
- Shareholder Votes
  Genprex, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-27
  source text: The proposal to ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 25,044,860 1,105,061 230,355 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923018626/0001437749-23-018626-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.